These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 23660123)

  • 1. Safety and tolerability of an intratumorally injected DNAzyme, Dz13, in patients with nodular basal-cell carcinoma: a phase 1 first-in-human trial (DISCOVER).
    Cho EA; Moloney FJ; Cai H; Au-Yeung A; China C; Scolyer RA; Yosufi B; Raftery MJ; Deng JZ; Morton SW; Hammond PT; Arkenau HT; Damian DL; Francis DJ; Chesterman CN; Barnetson RS; Halliday GM; Khachigian LM
    Lancet; 2013 May; 381(9880):1835-43. PubMed ID: 23660123
    [TBL] [Abstract][Full Text] [Related]  

  • 2. First-in-human trial of Dz13 for nodular basal-cell carcinoma.
    Grassi G; Grassi M
    Lancet; 2013 May; 381(9880):1797-8. PubMed ID: 23660122
    [No Abstract]   [Full Text] [Related]  

  • 3. DNAzyme targeting c-jun suppresses skin cancer growth.
    Cai H; Santiago FS; Prado-Lourenco L; Wang B; Patrikakis M; Davenport MP; Maghzal GJ; Stocker R; Parish CR; Chong BH; Lieschke GJ; Wong TW; Chesterman CN; Francis DJ; Moloney FJ; Barnetson RS; Halliday GM; Khachigian LM
    Sci Transl Med; 2012 Jun; 4(139):139ra82. PubMed ID: 22723462
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rogaratinib in patients with advanced cancers selected by FGFR mRNA expression: a phase 1 dose-escalation and dose-expansion study.
    Schuler M; Cho BC; Sayehli CM; Navarro A; Soo RA; Richly H; Cassier PA; Tai D; Penel N; Nogova L; Park SH; Schostak M; Gajate P; Cathomas R; Rajagopalan P; Grevel J; Bender S; Boix O; Nogai H; Ocker M; Ellinghaus P; Joerger M
    Lancet Oncol; 2019 Oct; 20(10):1454-1466. PubMed ID: 31405822
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of deoxyribozymes targeting c-Jun on solid tumor growth and angiogenesis in rodents.
    Zhang G; Dass CR; Sumithran E; Di Girolamo N; Sun LQ; Khachigian LM
    J Natl Cancer Inst; 2004 May; 96(9):683-96. PubMed ID: 15126605
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Melanoma protective antitumor immunity activated by catalytic DNA.
    Cai H; Cho EA; Li Y; Sockler J; Parish CR; Chong BH; Edwards J; Dodds TJ; Ferguson PM; Wilmott JS; Scolyer RA; Halliday GM; Khachigian LM
    Oncogene; 2018 Sep; 37(37):5115-5126. PubMed ID: 29844573
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy, rate of tumor response, and safety of a short course (12-24 weeks) of oral vismodegib in various histologic subtypes (infiltrative, nodular, and superficial) of high-risk or locally advanced basal cell carcinoma, in an open-label, prospective case series clinical trial.
    Fosko SW; Chu MB; Armbrecht E; Galperin T; Potts GA; Mattox A; Kurta A; Polito K; Slutsky JB; Burkemper NM; Hurley MY
    J Am Acad Dermatol; 2020 Apr; 82(4):946-954. PubMed ID: 31836564
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of proliferation and migration of tumor cells through phenylboronic acid-functionalized polyamidoamine-mediated delivery of a therapeutic DNAzyme Dz13.
    Yang J; Zhang J; Xing J; Shi Z; Han H; Li Q
    Int J Nanomedicine; 2019; 14():6371-6385. PubMed ID: 31496692
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The SINS trial: a randomised controlled trial of excisional surgery versus imiquimod 5% cream for nodular and superficial basal cell carcinoma.
    Ozolins M; Williams HC; Armstrong SJ; Bath-Hextall FJ
    Trials; 2010 Apr; 11():42. PubMed ID: 20409337
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Surgical excision versus imiquimod 5% cream for nodular and superficial basal-cell carcinoma (SINS): a multicentre, non-inferiority, randomised controlled trial.
    Bath-Hextall F; Ozolins M; Armstrong SJ; Colver GB; Perkins W; Miller PS; Williams HC;
    Lancet Oncol; 2014 Jan; 15(1):96-105. PubMed ID: 24332516
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Destroying c-jun Messenger: new insights into biological mechanisms of DNAzyme function.
    Khachigian LM; Cai H; Moloney FJ; Parish CR; Chong BH; Stocker R; Barnetson RS; Halliday GM
    Oncotarget; 2012 Jun; 3(6):594-5. PubMed ID: 22805148
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Open study of the efficacy and mechanism of action of topical imiquimod in basal cell carcinoma.
    Vidal D; Matías-Guiu X; Alomar A
    Clin Exp Dermatol; 2004 Sep; 29(5):518-25. PubMed ID: 15347339
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of topical 5% imiquimod cream for the treatment of nodular basal cell carcinoma: comparison of dosing regimens.
    Shumack S; Robinson J; Kossard S; Golitz L; Greenway H; Schroeter A; Andres K; Amies M; Owens M
    Arch Dermatol; 2002 Sep; 138(9):1165-71. PubMed ID: 12224977
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sequence-related off-target effect of Dz13 against human tumor cells and safety in adult and fetal mice following systemic administration.
    Dass CR; Choong PF
    Oligonucleotides; 2010 Apr; 20(2):51-60. PubMed ID: 20148692
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vismodegib in patients with advanced basal cell carcinoma (STEVIE): a pre-planned interim analysis of an international, open-label trial.
    Basset-Seguin N; Hauschild A; Grob JJ; Kunstfeld R; Dréno B; Mortier L; Ascierto PA; Licitra L; Dutriaux C; Thomas L; Jouary T; Meyer N; Guillot B; Dummer R; Fife K; Ernst DS; Williams S; Fittipaldo A; Xynos I; Hansson J
    Lancet Oncol; 2015 Jun; 16(6):729-36. PubMed ID: 25981813
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Imiquimod 5% cream for the treatment of superficial and nodular basal cell carcinoma: randomized studies comparing low-frequency dosing with and without occlusion.
    Sterry W; Ruzicka T; Herrera E; Takwale A; Bichel J; Andres K; Ding L; Thissen MR
    Br J Dermatol; 2002 Dec; 147(6):1227-36. PubMed ID: 12452875
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Photodynamic therapy versus topical imiquimod versus topical fluorouracil for treatment of superficial basal-cell carcinoma: a single blind, non-inferiority, randomised controlled trial.
    Arits AH; Mosterd K; Essers BA; Spoorenberg E; Sommer A; De Rooij MJ; van Pelt HP; Quaedvlieg PJ; Krekels GA; van Neer PA; Rijzewijk JJ; van Geest AJ; Steijlen PM; Nelemans PJ; Kelleners-Smeets NW
    Lancet Oncol; 2013 Jun; 14(7):647-54. PubMed ID: 23683751
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of the hedgehog pathway in advanced basal-cell carcinoma.
    Von Hoff DD; LoRusso PM; Rudin CM; Reddy JC; Yauch RL; Tibes R; Weiss GJ; Borad MJ; Hann CL; Brahmer JR; Mackey HM; Lum BL; Darbonne WC; Marsters JC; de Sauvage FJ; Low JA
    N Engl J Med; 2009 Sep; 361(12):1164-72. PubMed ID: 19726763
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase I clinical trial demonstrates that nfP2X
    Gilbert SM; Gidley Baird A; Glazer S; Barden JA; Glazer A; Teh LC; King J
    Br J Dermatol; 2017 Jul; 177(1):117-124. PubMed ID: 28150889
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dz13: c-Jun downregulation and tumour cell death.
    Elahy M; Dass CR
    Chem Biol Drug Des; 2011 Dec; 78(6):909-12. PubMed ID: 21722318
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.